Isoray (ISR) Stock Price, News & Analysis

Company Overview

IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.28 to $0.42
• 52-Week Range: N/A
• Volume: 145,000 shs
• Average Volume: 290,697 shs
• Market Capitalization: $54.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ISR Stock Analysis - Frequently Asked Questions

How were Isoray's earnings last quarter?

Isoray, Inc. (NYSE:ISR) issued its earnings results on Wednesday, November, 10th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01. The firm earned $2.56 million during the quarter, compared to the consensus estimate of $2.58 million. Isoray had a negative trailing twelve-month return on equity of 17.12% and a negative net margin of 115.91%.

What other stocks do shareholders of Isoray own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Isoray investors own include Brainstorm Cell Therapeutics (BCLI), OPKO Health (OPK), Tesla (TSLA), Meta Platforms (META), Tonix Pharmaceuticals (TNXP) and Nano Dimension (NNDM).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 5/17/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: N/A
• Current Symbol: NYSE:ISR
• CIK: 728387
• Web: isoray.com
• Phone: (509) 375-1202
• Fax: 509-267-3670
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,270,000.00
• Net Margins: -115.91%
• Pretax Margin: -91.45%
• Return on Equity: -17.12%
• Return on Assets: -16.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.38
• Quick Ratio: 13.99

Sales & Book Value

• Annual Sales: $10.80 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.43 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 142,110,000
• Free Float: 138,674,000
• Market Cap: $54.57 million
• Optionable: Not Optionable
• Beta: 1.48